SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 235 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.09 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $468,876 | -17.0% | 15,598 | 0.0% | 0.52% | -25.5% |
| Q1 2023 | $565,116 | -28.9% | 15,598 | -30.0% | 0.69% | -10.8% |
| Q4 2022 | $795,084 | +4.6% | 22,290 | 0.0% | 0.78% | +2.6% |
| Q3 2022 | $760,000 | +16.7% | 22,290 | -1.0% | 0.76% | +25.7% |
| Q2 2022 | $651,000 | -22.2% | 22,522 | -13.1% | 0.60% | -1.1% |
| Q1 2022 | $837,000 | -35.3% | 25,910 | -46.6% | 0.61% | +18.9% |
| Q3 2021 | $1,293,000 | -13.4% | 48,500 | 0.0% | 0.51% | +6.2% |
| Q2 2021 | $1,493,000 | +17.6% | 48,500 | 0.0% | 0.48% | +8.3% |
| Q1 2021 | $1,270,000 | -27.1% | 48,500 | -42.0% | 0.44% | -13.9% |
| Q3 2020 | $1,743,000 | -12.2% | 83,632 | 0.0% | 0.52% | -22.0% |
| Q2 2020 | $1,986,000 | +32.0% | 83,632 | 0.0% | 0.66% | +4.9% |
| Q1 2020 | $1,505,000 | -19.3% | 83,632 | +6.4% | 0.63% | -3.7% |
| Q4 2019 | $1,865,000 | -10.4% | 78,631 | +3.8% | 0.66% | -17.3% |
| Q3 2019 | $2,081,000 | +3.3% | 75,765 | +20.4% | 0.79% | +7.5% |
| Q2 2019 | $2,015,000 | +39.4% | 62,919 | +40.9% | 0.74% | +15.3% |
| Q1 2019 | $1,445,000 | 0.0% | 44,665 | 0.0% | 0.64% | +3.7% |
| Q4 2018 | $1,445,000 | -29.4% | 44,665 | +8.9% | 0.62% | -12.1% |
| Q3 2018 | $2,048,000 | -7.1% | 41,004 | +8.6% | 0.70% | -13.9% |
| Q2 2018 | $2,204,000 | +11.8% | 37,765 | -12.2% | 0.82% | +0.6% |
| Q1 2018 | $1,971,000 | +69.5% | 43,025 | +47.4% | 0.81% | +61.4% |
| Q4 2017 | $1,163,000 | -0.3% | 29,180 | 0.0% | 0.50% | -3.6% |
| Q3 2017 | $1,167,000 | -7.2% | 29,180 | 0.0% | 0.52% | -9.1% |
| Q2 2017 | $1,258,000 | -0.4% | 29,180 | -27.7% | 0.57% | +13.9% |
| Q1 2017 | $1,263,000 | +808.6% | 40,359 | +140.3% | 0.50% | +673.8% |
| Q4 2014 | $139,000 | -4.8% | 16,796 | 0.0% | 0.06% | – |
| Q3 2014 | $146,000 | -20.7% | 16,796 | 0.0% | 0.00% | -100.0% |
| Q2 2014 | $184,000 | – | 16,796 | – | 0.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ASHFORD CAPITAL MANAGEMENT INC | 921,962 | $33,402,683 | 5.00% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 423,500 | $15,326,465 | 4.28% |
| ARMISTICE CAPITAL, LLC | 4,350,000 | $157,600,500 | 2.27% |
| S&T BANK/PA | 223,775 | $8,107 | 1.46% |
| Aristotle Capital Boston, LLC | 1,155,149 | $41,851,071 | 1.29% |
| Tributary Capital Management, LLC | 353,671 | $12,813,500 | 1.19% |
| Bridge City Capital, LLC | 62,790 | $2,274,882 | 1.14% |
| RICE HALL JAMES & ASSOCIATES, LLC | 551,285 | $19,973,056 | 1.14% |
| Intrinsic Edge Capital Management LLC | 289,704 | $10,495,976 | 1.05% |
| Parkman Healthcare Partners LLC | 131,878 | $4,777,940 | 1.04% |